Payment overview · 2025
General Payments
$2,214.61
104 reported records · 21 companies
Healthcare provider profile · identity verified
Ulhas T Deven, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DUNNELLON, FL · NPI 1235120338
Verified facts
What the public records show
CMS Open Payments records show Ulhas T Deven, M.D. received $2,214.61 in general payments during 2025 across 104 reported records.
ABBVIE INC. accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Nexletol, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 228 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 109 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 197 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 184 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 409 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $450.33 | 20.3% | 21 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $379.39 | 17.1% | 7 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $273.05 | 12.3% | 17 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $137.96 | 6.2% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $136.67 | 6.2% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $133.10 | 6.0% | 6 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $123.06 | 5.6% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $102.54 | 4.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $97.90 | 4.4% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $59.66 | 2.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $56.63 | 2.6% | 3 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $47.24 | 2.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $41.71 | 1.9% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $35.17 | 1.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $31.57 | 1.4% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $22.10 | 1.0% | 1 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $21.26 | 1.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $19.90 | 0.9% | 1 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $16.12 | 0.7% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.55 | 0.7% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.70 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,214.61 | 104 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $337.60 | 16 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $316.08 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $296.08 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $281.93 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $189.89 | 12 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $142.85 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $137.96 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $133.80 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $133.10 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $123.06 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $122.45 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $117.88 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.73 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $112.73 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $102.54 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $102.54 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $97.90 | 5 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $83.16 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $56.63 | 3 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $47.24 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $41.71 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $39.57 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $35.17 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $31.57 | 2 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| LOPRESSOR Normalized: lopressor |
Drug | Validus Pharmaceuticals LLC | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| RALDESY Normalized: raldesy |
Drug | Validus Pharmaceuticals LLC | $21.26 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $15.55 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 228 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 197 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 58 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 178 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 40 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 139 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
19 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
63 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
228 | 67 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
109 | 30 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 46 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
139 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
197 | 46 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
95 | 23 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
184 | 32 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
178 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
40 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
409 | 86 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
76 | 76 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1614 | 453 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1059 | 317 |
| Amlodipine Besylate | Amlodipine Besylate | 949 | 288 |
| Levothyroxine Sodium | Levothyroxine Sodium | 894 | 256 |
| Omeprazole | Omeprazole | 776 | 266 |
| Lisinopril | Lisinopril | 766 | 231 |
| Metoprolol Succinate | Metoprolol Succinate | 737 | 188 |
| Losartan Potassium | Losartan Potassium | 719 | 222 |
| Gabapentin | Gabapentin | 660 | 203 |
| Metformin Hcl | Metformin Hcl | 499 | 158 |
| Metoprolol Tartrate | Metoprolol Tartrate | 492 | 149 |
| Trazodone Hcl | Trazodone Hcl | 458 | 139 |
| Potassium Chloride | Potassium Chloride | 453 | 146 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 436 | 192 |
| Eliquis | Apixaban | 409 | 86 |
| Prednisone | Prednisone | 399 | 256 |
| Famotidine | Famotidine | 377 | 133 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 372 | 75 |
| Tramadol Hcl | Tramadol Hcl | 369 | 107 |
| Furosemide | Furosemide | 361 | 119 |
| Pantoprazole Sodium | Pantoprazole Sodium | 361 | 126 |
| Azithromycin | Azithromycin | 347 | 264 |
| Clopidogrel | Clopidogrel Bisulfate | 343 | 102 |
| Tamsulosin Hcl | Tamsulosin Hcl | 328 | 110 |
| Ezetimibe | Ezetimibe | 327 | 117 |
| Meloxicam | Meloxicam | 308 | 138 |
| Spironolactone | Spironolactone | 304 | 103 |
| Alprazolam | Alprazolam | 288 | 75 |
| Simvastatin | Simvastatin | 276 | 78 |
| Alendronate Sodium | Alendronate Sodium | 250 | 78 |
| Valsartan | Valsartan | 230 | 68 |
| Farxiga | Dapagliflozin Propanediol | 228 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 214 | 66 |
| Mirtazapine | Mirtazapine | 209 | 62 |
| Sertraline Hcl | Sertraline Hcl | 203 | 69 |
| Carvedilol | Carvedilol | 200 | 61 |
| Jardiance | Empagliflozin | 197 | 46 |
| Montelukast Sodium | Montelukast Sodium | 197 | 62 |
| Citalopram Hbr | Citalopram Hydrobromide | 194 | 70 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 193 | 142 |
| Allopurinol | Allopurinol | 187 | 57 |
| Entresto | Sacubitril/Valsartan | 184 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 182 | 62 |
| Ozempic | Semaglutide | 178 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 178 | 59 |
| Escitalopram Oxalate | Escitalopram Oxalate | 170 | 56 |
| Hydrochlorothiazide | Hydrochlorothiazide | 166 | 56 |
| Zolpidem Tartrate | Zolpidem Tartrate | 165 | 51 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 73 |
| Finasteride | Finasteride | 160 | 46 |
| Buspirone Hcl | Buspirone Hcl | 159 | 70 |
| Atenolol | Atenolol | 152 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 85 |
| Ibuprofen | Ibuprofen | 150 | 66 |
| Xarelto | Rivaroxaban | 145 | 33 |
| Chlorthalidone | Chlorthalidone | 143 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 139 | 45 |
| Donepezil Hcl | Donepezil Hcl | 130 | 47 |
| Ropinirole Hcl | Ropinirole Hcl | 127 | 37 |
| Warfarin Sodium | Warfarin Sodium | 124 | 21 |
| Amoxicillin | Amoxicillin | 122 | 94 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 121 | 100 |
| Ondansetron Hcl | Ondansetron Hcl | 118 | 73 |
| Cephalexin | Cephalexin | 117 | 95 |
| Clonazepam | Clonazepam | 117 | 23 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 117 | 38 |
| Symbicort | Budesonide/Formoterol Fumarate | 109 | 30 |
| Glipizide | Glipizide | 106 | 40 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 105 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 102 | 31 |
| Doxycycline Hyclate | Doxycycline Hyclate | 96 | 77 |
| Pregabalin | Pregabalin | 96 | 30 |
| Baclofen | Baclofen | 95 | 31 |
| Trulicity | Dulaglutide | 95 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 41 |
| Clonidine Hcl | Clonidine Hcl | 89 | 36 |
| Digoxin | Digoxin | 88 | 14 |
| Meclizine Hcl | Meclizine Hcl | 88 | 51 |
| Celecoxib | Celecoxib | 86 | 32 |
| Bumetanide | Bumetanide | 85 | 29 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | 17 |
| Nystatin | Nystatin | 85 | 40 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 85 | 35 |
| Levofloxacin | Levofloxacin | 84 | 66 |
| Oxycodone Hcl | Oxycodone Hcl | 84 | 19 |
| Bupropion Xl | Bupropion Hcl | 83 | 25 |
| Levetiracetam | Levetiracetam | 82 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 81 | 30 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 81 | 37 |
| Lorazepam | Lorazepam | 81 | 22 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 81 | 57 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 80 | 20 |
| Glimepiride | Glimepiride | 80 | 24 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 79 | 22 |
| Nitroglycerin | Nitroglycerin | 79 | 51 |
| Methylprednisolone | Methylprednisolone | 78 | 66 |
| Paroxetine Hcl | Paroxetine Hcl | 77 | 21 |
| Vascepa | Icosapent Ethyl | 77 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 76 | 76 |
| Quetiapine Fumarate | Quetiapine Fumarate | 74 | 27 |
| Temazepam | Temazepam | 69 | 15 |
| Naproxen | Naproxen | 68 | 33 |
| Aripiprazole | Aripiprazole | 65 | 31 |
| Methocarbamol | Methocarbamol | 65 | 40 |
| Divalproex Sodium | Divalproex Sodium | 64 | 16 |
| Januvia | Sitagliptin Phosphate | 64 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 63 | 23 |
| Myrbetriq | Mirabegron | 63 | 13 |
| Lamotrigine | Lamotrigine | 62 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 62 | 23 |
| Topiramate | Topiramate | 62 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 61 | 20 |
| Lovastatin | Lovastatin | 61 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 61 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 60 | 30 |
| Linzess | Linaclotide | 59 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 59 | 21 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 25 |
| Labetalol Hcl | Labetalol Hcl | 58 | 15 |
| Memantine Hcl | Memantine Hcl | 58 | suppressed |
| Mounjaro | Tirzepatide | 58 | 12 |
| Nifedipine Er | Nifedipine | 58 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 58 | 22 |
| Benazepril Hcl | Benazepril Hcl | 56 | 17 |
| Midodrine Hcl | Midodrine Hcl | 53 | 15 |
| Propranolol Hcl Er | Propranolol Hcl | 53 | 16 |
| Fluconazole | Fluconazole | 52 | 35 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 23 |
| Metformin Hcl Er | Metformin Hcl | 51 | 14 |
| Ranolazine Er | Ranolazine | 51 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 51 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 49 | 14 |
| Propranolol Hcl | Propranolol Hcl | 49 | 17 |
| Sildenafil Citrate | Sildenafil Citrate | 49 | 15 |
| Enalapril Maleate | Enalapril Maleate | 48 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 48 | 12 |
| Acyclovir | Acyclovir | 47 | 21 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | 11 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 47 | 15 |
| Oxybutynin Chloride | Oxybutynin Chloride | 47 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 14 |
| Metronidazole | Metronidazole | 46 | 33 |
| Risperidone | Risperidone | 45 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 44 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 43 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 43 | 14 |
| Ketoconazole | Ketoconazole | 43 | 22 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 43 | 18 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 42 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 42 | 19 |
| Latanoprost | Latanoprost | 42 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 42 | 11 |
| Vraylar | Cariprazine Hcl | 42 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 41 | 19 |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 40 | 12 |
| Rybelsus | Semaglutide | 40 | 15 |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 38 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 38 | 14 |
| Sucralfate | Sucralfate | 38 | 18 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 38 | 32 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | 17 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 37 | 22 |
| Fenofibrate | Fenofibrate | 36 | suppressed |
| Hydrocortisone | Hydrocortisone | 36 | suppressed |
| Insulin Lispro | Insulin Lispro | 36 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 36 | 14 |
| Estradiol | Estradiol | 35 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 19 |
| Glyxambi | Empagliflozin/Linagliptin | 33 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Sotalol | Sotalol Hcl | 33 | suppressed |
| Torsemide | Torsemide | 33 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | 13 |
| Folic Acid | Folic Acid | 31 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 31 | 11 |
| Ondansetron Odt | Ondansetron | 31 | 20 |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | 19 |
| Cefuroxime | Cefuroxime Axetil | 30 | 24 |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 29 | suppressed |
| Primidone | Primidone | 29 | 14 |
| Terbinafine Hcl | Terbinafine Hcl | 29 | 17 |
| Tresiba Flextouch U-100 | Insulin Degludec | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Novolog | Insulin Aspart | 28 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 28 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 27 | 18 |
| Benzonatate | Benzonatate | 26 | 13 |
| Diazepam | Diazepam | 26 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 23 |
| Erythromycin | Erythromycin Base | 25 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | 11 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 24 | 12 |
| Bydureon Bcise | Exenatide Microspheres | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 17 |
| Spiriva Respimat | Tiotropium Bromide | 24 | suppressed |
| Eszopiclone | Eszopiclone | 23 | 11 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 22 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 20 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Metolazone | Metolazone | 19 | 11 |
| Prazosin Hcl | Prazosin Hcl | 19 | suppressed |
| Prolia | Denosumab | 19 | 12 |
| Timolol Maleate | Timolol Maleate | 19 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | 12 |
| Epinephrine | Epinephrine | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 18 | 11 |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Repatha Sureclick | Evolocumab | 17 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 16 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Nyamyc | Nystatin | 16 | 12 |
| Tradjenta | Linagliptin | 16 | suppressed |
| Xifaxan | Rifaximin | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 15 | suppressed |
| Nystop | Nystatin | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 14 | suppressed |
| Dalfampridine Er | Dalfampridine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 14 | suppressed |
| Ibu | Ibuprofen | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Olanzapine | Olanzapine | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Cimetidine | Cimetidine | 13 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 13 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Nexletol | Bempedoic Acid | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Zaleplon | Zaleplon | 13 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 12 | 12 |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Jantoven | Warfarin Sodium | 11 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 11 | 11 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Permethrin | Permethrin | 11 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,214.61 · 104 records | ABBVIE INC. | AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, Cologuard Collection Kit, FARXIGA, ISTURISA, JARDIANCE, Kerendia, LEQVIO, LOPRESSOR, LYBALVI, MOUNJARO, NEXLETOL, NUPLAZID, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, QULIPTA, RALDESY, REPATHA, Rybelsus, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, XHANCE, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error